These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 29495966)

  • 41. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.
    Stern M; de Wreede LC; Brand R; van Biezen A; Dreger P; Mohty M; de Witte TM; Kröger N; Ruutu T
    Leukemia; 2014 Nov; 28(11):2235-40. PubMed ID: 24781016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

  • 45. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
    Chamseddine AN; Willekens C; De Botton S; Bourhis JH
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma.
    Wei R; Fang J; Shi W; Lu X; Wu Y; Jiang S; Zhang A; Liao S; Qin C; Cui G; Xia L
    Cancer Med; 2023 May; 12(9):10499-10511. PubMed ID: 36992548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
    Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
    J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
    Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
    Li QB; Li L; You Y; Chen ZC; Xia LH; Zou P
    Acta Pharmacol Sin; 2009 Oct; 30(10):1471-8. PubMed ID: 19767767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
    Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
    Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
    J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective.
    Ma R; Liu XT; Chang YJ
    Expert Rev Hematol; 2022 Sep; 15(9):789-803. PubMed ID: 36106497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
    Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
    Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hamdi A; Mawad R; Bassett R; di Stasi A; Ferro R; Afrough A; Ram R; Dabaja B; Rondon G; Champlin R; Sandmaier BM; Doney K; Bar M; Kebriaei P
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1767-71. PubMed ID: 25017763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DLI or second transplant.
    Greinix HT
    Ann Hematol; 2002; 81 Suppl 2():S34-5. PubMed ID: 12611068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.